readthroughSign in
Nov 12, 2026Quarterly update

CorMedix to acquire Heron Therapeutics assets, reports Q3 2026 results

CorMedix disclosed on November 12, 2026 that it agreed on November 9 to buy substantially all of Heron's assets, alongside third-quarter revenue of $54.5 million.

CorMedix Therapeutics reported on November 12, 2026 that CorMedix and Heron Therapeutics, Inc. announced on November 9, 2026, that they have entered into a definitive asset purchase agreement under which CorMedix will acquire substantially all of the assets of Heron.1 CorMedix said the transaction is expected to be immediately accretive to earnings and free cash flow upon closing, which it anticipates in the first quarter of 2027, subject to approval by Heron's stockholders, regulatory clearance and other customary closing conditions.1

To help fund the acquisition, CorMedix entered into a term loan agreement to provide up to $150 million in non-dilutive capital, of which the Company expects to utilize $75 million upon closing.1 Chairman and CEO Joseph Todisco said the deal carries an anticipated revenue contribution of between $125 million and $150 million for the full-year 2027, which the company said would effectively double its non-DefenCath annual product revenue.1

On the regulatory front, CorMedix announced on October 19, 2026, that in collaboration with its global development partner Mundipharma, the FDA accepted for review the submission of the sNDA for an expanded indication of REZZAYO for the prophylaxis of invasive fungal disease.1 The FDA granted Priority Review to the REZZAYO prophylaxis sNDA, with a PDUFA date in the first quarter of 2027,1 and the company said that if approved, it plans to commence promotional efforts in the second half of 2027.1

On guidance, the Company maintained full-year 2026 consolidated revenue guidance of $325 to $345 million, narrowed full-year adjusted EBITDA guidance to a range of $130 to $140 million from $125 to $140 million, and reduced cash-based OpEx guidance to $140 to $145 million from $145 to $155 million.1 However, citing recently announced changes to the CMS reimbursement framework, the Company said it would suspend any previously issued 2027 DefenCath revenue guidance and defer future guidance until early 2027, when it expects better visibility into 2027 utilization and pricing for customers and potential upside from Medicare Advantage contracting.1

On cash, cash and short-term investments, excluding restricted cash, totaled $355.2 million at September 30, 2026.1 The Company said it believes it has sufficient resources to fund operations for at least twelve months from the issuance of its Form 10-Q.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.